GSK plc
NYSE:GSKDrug Manufacturers - General
-$1.34 today
- Market cap
- $97.53B
- Beta
- 0.29
- P/E (TTM)
- 13.3
- EPS (TTM)
- $1.45
- Dividend yield
- 3.48%
Volume 2.02M
Average 4.07M
GSK Total Debt
Short-term and long-term borrowings combined.
GSK plcNYSE: GSK
Total Debt · Q2 FY2026 · quarter ended Jun 2026
Total debt falls 23.8% from a year ago
Total debt stood at £18.13B at the end of Q2 FY2026, down 23.8% from a year earlier and down 27.9% from the prior quarter. Over 3 fiscal years it compounded at -5.5% a year.
Context
- Total debt amounted to 29.5% of total assets at the end of Q2 FY2026, up 0.3 pp from a year earlier.
- Total debt increased in 2 of the last 3 fiscal years.
What to watch
Whether total debt keeps falling in the next quarterly balance sheet after a -23.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
GBP · from the balance sheet
- Latest · FY2025
- 17.69B GBP
- Year-over-year change
- +4.1%
- 4-year CAGR
- -14.3%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.69B | +4.1% |
| FY2024 | 2024-12-31 | 16.99B | -26.0% |
| FY2023 | 2023-12-31 | 22.97B | +9.4% |
| FY2022 | 2022-12-31 | 20.99B | -35.9% |
| FY2021 | 2021-12-31 | 32.74B | — |
Total Debt vs competitors
How GSK compares with its peers on the latest reported figures
- Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -23.8% is the lowest of 10, against a peer median of +5.8%.
- Total debt amounts to 29.5% of total assets for GSK, versus a peer median of 31.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | DKK 140.13B DKK | +41.2% | +71.9% | 23.6% | |
| Jun 2026 | $63.19B USD | +2.3% | +24.6% | 31.4% | |
| Jun 2026 | $57.3B USD | +2.0% | +11.9% | 59.9% | |
| Jun 2026 | $54.91B USD | +37.6% | +37.8% | 38.6% | |
| Jun 2026 | $53.91B USD | +52.3% | +16.5% | 41.5% | |
| Jun 2026 | $49.01B USD | +50.2% | +9.9% | 40.2% | |
| Sep 2026 | $44.65B USD | -2.5% | +6.5% | 22.6% | |
| Sep 2026 | $34.13B USD | +4.5% | +0.6% | 28.5% | |
| Jun 2026 | €23.58B EUR | +5.8% | -1.4% | 18.3% | |
| Jun 2026 | £18.13B GBP | -23.8% | -5.5% | 29.5% | |
| Peer median (excluding GSK) | — | +5.8% | +11.9% | 31.4% | |
Competitors are the stored peer set for GSK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 5.79B | 3.72B | 3.74B | 3.69B | 3.39B |
| Short-term Investments | 82.62M | 4.15B | 2.86B | 21M | 8.98M |
| Net Receivables | 10.88B | 6.22B | 9.44B | 6B | 7.75B |
| Inventory | 7.83B | 5.15B | 7.01B | 5.67B | 5.91B |
| Other Current Assets | 284.44M | 1.1B | 262.61M | 1.23B | 420.26M |
| Total Current Assets | 25.29B | 20.77B | 23.77B | 17B | 17.48B |
| Property, Plant & Equipment (Net) | 14.45B | 9.62B | 12.69B | 10.07B | 10.03B |
| Goodwill | 14.29B | 7.05B | 8.68B | 6.98B | 7.01B |
| Intangible Assets | 40.74B | 14.32B | 18.83B | 15.52B | 16.72B |
| Long-term Investments | 4.29B | (2.61B) | 2.73B | 1.21B | 1.12B |
| Tax Assets | 7.07B | 5.66B | 7.71B | 6.76B | 6.51B |
| Other Non-current Assets | 1B | 5.35B | 808.22M | 1.93B | 2.14B |
| Total Non-current Assets | 81.85B | 39.38B | 51.45B | 42.47B | 43.53B |
| Total Assets | 107.14B | 60.15B | 75.22B | 59.46B | 61.01B |
| Account Payables | 6.14B | 3.87B | 4.74B | 3.46B | 15.35B |
| Short-term Debt | 4.88B | 3.79B | 3.59B | 2.18B | 3.01B |
| Tax Payables | 489M | 471M | 500M | 703M | 0 |
| Deferred Revenue | 415.82M | 0 | 283.01M | 0 | 0 |
| Other Current Liabilities | 17.97B | 14.1B | 15.25B | 14.76B | 2.5B |
| Total Current Liabilities | 32.06B | 22.81B | 26.86B | 21.7B | 21.35B |
| Long-term Debt | 26.76B | 16.19B | 18.04B | 13.7B | 14.68B |
| Deferred Tax Liabilities | 4.82B | 289M | 396.46M | 382M | 290.49M |
| Deferred Revenue (Non-current) | 115.13M | 83M | 323.8M | 165M | 0 |
| Other Non-current Liabilities | 13.38B | 9.83B | 11.95B | 9.5B | 8.69B |
| Total Non-current Liabilities | 46.17B | 27.24B | 32.05B | 24.68B | 23.66B |
| Total Liabilities | 78.23B | 50.05B | 58.91B | 46.38B | 45.02B |
| Common Stock | 1.82B | 1.35B | 1.72B | 1.35B | 1.35B |
| Retained Earnings | 13.26B | 4.36B | 9.23B | 7.8B | 10.19B |
| Accumulated OCI | 869.56M | 0 | 2.04B | 0 | 0 |
| Other Stockholders Equity | 0 | 1.45B | 0 | 1.05B | 1.32B |
| Minority Interest | 8.52B | (502M) | (703.69M) | (585M) | (420.26M) |
| Total Equity | 28.91B | 10.1B | 16.31B | 13.09B | 15.93B |
| Total Debt | 32.74B | 20.99B | 22.97B | 16.99B | 17.69B |
| Net Debt | 26.95B | 17.26B | 19.23B | 13.29B | 14.3B |
GSK plc
NYSE:GSK
Intrinsic Alpha fair value
Locked
Current Price
$48.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.